The acquisition will enable pharma companies to drive more precise, scalable, and measurable outcomes
Indegene announced the strategic acquisition of BioPharm, a Pennsylvania-based specialised marketing services agency and part of Omnicom Health Group. This acquisition by ILSL, a subsidiary of Indegene Limited, strengthens Indegene’s commercialisation portfolio with AdTech, combining AI and digital advertising, enabling pharma companies to drive more precise, scalable, and measurable outcomes.
“BioPharm has built an impressive growth flywheel, with advanced tech capabilities, deep therapeutic expertise, and long-standing client relationships. This acquisition reinforces our position as the preferred tech-native, commercialisation partner for the life sciences industry, helping clients unlock greater strategic value from their marketing and AdTech investments,” said Manish Gupta, Chairman and CEO, Indegene. “I am delighted to welcome Steve and the BioPharm team to the Indegene family, and we look forward to shaping the future of AI-led commercialization together.”
“Indegene is a natural home for us, given their client-focused, innovation-first, employee-centric culture – backed by strong technology platforms, data and analytics capabilities, deep medical expertise, marquee client base and a global delivery model. And, we are very excited to join the larger Indegene family at a pivotal time for the industry”, said Steve Carickhoff, President, BioPharm.
